1-3 of 3
Ahmed Nadeem, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes,

Guillermo Garcia-Manero, Elias Jabbour, Gautam Borthakur, Stefan Faderl, MD, Zeev Estrov, Lucy Godley, MD, PhD, Nashat Y. Gabrail, MD, Jesus G. Berdeja, MD, Ahmed Nadeem, MD, Karen Stein, MD, MPH, Yvonne Noble, RN, BS, Laurent Kassalow, MS, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2011) 118 (21): 3812.
https://doi.org/10.1182/blood.V118.21.3812.3812
Published: 2011
Journal Articles

A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS).

Guillermo Garcia-Manero, MD, Daniel R. Couriel, MD, Francesco Paolo Tambaro, MD, PhD, Nashat Gabrail, Ahmed Nadeem, MD, Tapan Kadia, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Stefan Faderl, MD, Willie Newsome, RN, Hui Yang, MD, PhD, Kevin Chen, Karen Stein, MD, Hagop Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 119.
https://doi.org/10.1182/blood.V114.22.119.119
Published: 2009
Journal Articles

Phase I Trial Examining Addition of Gemcitabine to CHOP in Intermediate Grade NHL.

John L. Reagan, MD, James N. Butera, MD, Alan G. Rosmarin, MD, Ahmed Nadeem, MD, Fred J. Schiffman, MD, William Sikov, MD, Eric Winer, MD, Anthony Mega, MD
Journal: Blood
Blood (2009) 114 (22): 4765.
https://doi.org/10.1182/blood.V114.22.4765.4765
Published: 2009